Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today participation in the following upcoming investor conferences:

• Morgan Stanley 21^st Annual Global Healthcare Conference, September 11-13, 2023, NY, NY:
  • Pipeline management will participate in 1x1s with investors during the conference.

• UBS Biotechnology Private Company Virtual Symposium, September 20-21, 2023:
  • Carmine Stengone, Pipeline’s CEO, will participate in a fireside chat on Thursday, September 21, 2023, at 10:30am ET.
  • Pipeline management will also participate in 1x1s with investors during the conference.

About Pipeline Therapeutics

Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair. The Company has a broad pipeline of programs to address multiple CNS disorders. In April 2023, Pipeline announced that it entered into a global license and development agreement with Janssen Pharmaceutica NV (Janssen) for its lead program, PIPE-307, a highly selective M1 antagonist, in central nervous system disorders. The Company’s lead wholly-owned program, PIPE-791, an LPA1 receptor antagonist, is advancing through Phase 1 testing to support treatment of neurological diseases.

For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230907148735/en/